Actively Recruiting
Glucose Profiles in Women With Polycystic Ovary Syndrome
Led by Centre Hospitalier Universitaire, Amiens · Updated on 2026-03-19
80
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Polycystic ovary syndrome (PCOS) is a common condition linked to metabolic problems, including insulin resistance and a higher risk of developing type 2 diabetes. PCOS has four different phenotypes (A-D), and some may have less risk of insulin resistance. This research aims to study glucose levels continuously to see how glucose profiles differ among these PCOS phenotypes using new monitoring technology. Participants in this study will use a Free-style Libre Pro sensor device to continuously monitor glucose levels for 14 days. The study compares four PCOS phenotypes based on combinations of symptoms such as irregular menstrual cycles, hyperandrogenism, and ovarian morphology or AMH levels. Additionally, an Age Reader device will analyze glycation end products related to glucose control. Women in the trial will be monitored over two weeks, with continuous glucose data collected through the sensor. Researchers will assess time spent within glucose target ranges, average blood sugar levels, variability, and presence of low blood sugar. Other tests include HbA1C, oral glucose tolerance, insulin resistance evaluation, and glycation product measurement. The study is non-randomized and open-label, with participation starting in January 2026 and ending in July 2027.
CONDITIONS
Brief Title
Glucose Profiles in Women With Polycystic Ovary Syndrome
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age over 18 years at inclusion
- Diagnosis of polycystic ovary syndrome with at least two of the following: irregular menstrual cycles, clinical or biological hyperandrogenism, polycystic ovary morphology by ultrasound or elevated AMH levels
- Agreement to wear the Free-style Libre Pro sensor
- Signed informed consent
You will not qualify if you...
- Pregnancy or breastfeeding
- Presence of other conditions such as hyperprolactinemia, thyroid disorders, Cushing's syndrome, congenital adrenal hyperplasia, virilizing tumors
- Existing diagnosis of diabetes
- Treatment within 3 months prior to inclusion with estrogen-progestin contraception, progestin contraception, antidiabetic drugs, inositol, or antiandrogens
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 14 days
Participants wear a Free-style Libre Pro glucose sensor for 14 days and undergo analysis of glycation end products using the AGE reader.
1 visit for sensor application and removal, plus 1 visit for AGE reader analysis
Trial Site Locations
Total: 1 location
1
CHRU Amiens
Salouël, France
Actively Recruiting
Research Team
A
Abdallah Al-Salameh, Pr
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
OTHER
Number of Arms
4
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here